Arry something is cooking it's real I am betting on a buyout
While I would love for that to be the case, the volume and movement today probably pertains to GSK disclosing today that their MEK inhibitor hit primary endpoint in its Phase 3 melanoma trial and GSK will be filing for approval soon. The market presumably takes this news as boding well for ARRY's own MEKs against melanoma (and possibly other indications).